JP5297202B2 - 結腸直腸癌の予後のための遺伝子発現マーカー - Google Patents

結腸直腸癌の予後のための遺伝子発現マーカー Download PDF

Info

Publication number
JP5297202B2
JP5297202B2 JP2008550454A JP2008550454A JP5297202B2 JP 5297202 B2 JP5297202 B2 JP 5297202B2 JP 2008550454 A JP2008550454 A JP 2008550454A JP 2008550454 A JP2008550454 A JP 2008550454A JP 5297202 B2 JP5297202 B2 JP 5297202B2
Authority
JP
Japan
Prior art keywords
expression
cancer
normalized
rna
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008550454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523028A5 (enExample
JP2009523028A (ja
Inventor
ウェイン コーウェンズ，
ジョッフル ビー． ベイカー，
キム クラーク，
ジェームス ハケット，
ドリュー ワトソン，
スンミュン パク，
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
エヌエスエービーピー ファウンデーション， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド, エヌエスエービーピー ファウンデーション， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2009523028A publication Critical patent/JP2009523028A/ja
Publication of JP2009523028A5 publication Critical patent/JP2009523028A5/ja
Application granted granted Critical
Publication of JP5297202B2 publication Critical patent/JP5297202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008550454A 2006-01-11 2007-01-11 結腸直腸癌の予後のための遺伝子発現マーカー Active JP5297202B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75839206P 2006-01-11 2006-01-11
US60/758,392 2006-01-11
US80027706P 2006-05-12 2006-05-12
US60/800,277 2006-05-12
US81007706P 2006-05-31 2006-05-31
US60/810,077 2006-05-31
PCT/US2007/000995 WO2007082099A2 (en) 2006-01-11 2007-01-11 Gene expression markers for colorectal cancer prognosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272400A Division JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー

Publications (3)

Publication Number Publication Date
JP2009523028A JP2009523028A (ja) 2009-06-18
JP2009523028A5 JP2009523028A5 (enExample) 2010-03-18
JP5297202B2 true JP5297202B2 (ja) 2013-09-25

Family

ID=38257063

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2008550454A Active JP5297202B2 (ja) 2006-01-11 2007-01-11 結腸直腸癌の予後のための遺伝子発現マーカー
JP2012272400A Active JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124950A Active JP5486719B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124949A Active JP5486718B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124951A Active JP5486720B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124952A Pending JP2013215201A (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124948A Active JP5486717B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2012272400A Active JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124950A Active JP5486719B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124949A Active JP5486718B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124951A Active JP5486720B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124952A Pending JP2013215201A (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124948A Active JP5486717B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー

Country Status (14)

Country Link
US (10) US7695913B2 (enExample)
EP (9) EP2412824B1 (enExample)
JP (7) JP5297202B2 (enExample)
KR (1) KR20090003178A (enExample)
AU (1) AU2007204826B2 (enExample)
BR (1) BRPI0706511A2 (enExample)
CA (1) CA2636984A1 (enExample)
DK (1) DK1974058T3 (enExample)
ES (1) ES2491222T3 (enExample)
IL (1) IL192794A (enExample)
MX (1) MX2008008973A (enExample)
NO (1) NO20083461L (enExample)
NZ (7) NZ593224A (enExample)
WO (1) WO2007082099A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506066A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
KR20090003178A (ko) * 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
US20090123920A1 (en) * 2007-11-08 2009-05-14 Maher Albitar Jak2 mutations
ES2332167B1 (es) 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2009123634A1 (en) * 2008-04-02 2009-10-08 Regents Of The University Of California Systems and methods for predicting response of biological samples
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009246398A1 (en) 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
US20100029748A1 (en) * 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
CN106978480A (zh) 2010-09-15 2017-07-25 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
AU2012209074A1 (en) * 2011-01-25 2013-07-11 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US10308980B2 (en) 2011-11-04 2019-06-04 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
AU2012344155A1 (en) 2011-11-28 2014-07-03 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Methods and kits for the prognosis of colorectal cancer
EP2794924B1 (en) 2011-12-22 2019-02-06 Baylor Research Institute Identification of mirna signatures in human colorectal cancer
US9822417B2 (en) 2012-01-09 2017-11-21 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
SG11201404390WA (en) 2012-01-31 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2013150167A2 (es) 2012-04-03 2013-10-10 Servicio Andaluz De Salud Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
ES2475366B1 (es) * 2012-12-10 2015-05-05 Fundación Imdea Alimentación Métodos y kits para el pronóstico del cáncer colorrectal
WO2014159797A1 (en) 2013-03-14 2014-10-02 Abbott Molecular Inc. Cell preparations and cell supports and their use in theranosis
WO2014191559A1 (en) * 2013-05-30 2014-12-04 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US10185809B1 (en) * 2013-10-15 2019-01-22 Iqvia Inc. Patient projection methodology
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
AU2015237229A1 (en) * 2014-03-28 2016-11-10 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016062892A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN107077536B (zh) 2014-10-24 2021-09-28 皇家飞利浦有限公司 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性
DE112014007209T5 (de) 2014-11-25 2017-08-03 Mitsubishi Electric Corporation Pneumatischer Antrieb
US20180148789A1 (en) * 2014-12-01 2018-05-31 University Of Southern California Methods for treating and assessing tumor invasion and metastasis
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
GB2545361B (en) 2015-04-10 2018-01-24 Applied Proteomics Inc Methods of assessing colorectal cancer status
CN108271422A (zh) * 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
JP7028763B2 (ja) 2015-08-14 2022-03-02 コーニンクレッカ フィリップス エヌ ヴェ 標的遺伝子発現の数学的モデリングを使用するＮＦｋＢ細胞シグナリング経路活性の評価
JP6332780B2 (ja) 2016-03-29 2018-05-30 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
BR112018073014A2 (pt) 2016-05-10 2019-02-19 Mayo Foundation For Medical Education And Research métodos e materiais para estadiamento e tratamento de câncer de pele
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
WO2018224731A1 (en) * 2017-06-05 2018-12-13 Ls Cancerdiag Oy A method for determining whether a subject is at risk to develop cancer and tools related thereto
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
WO2019173647A1 (en) 2018-03-08 2019-09-12 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and adminstering treatment protocols based thereon
KR102007450B1 (ko) * 2018-05-31 2019-08-05 한국과학기술연구원 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커
CA3107401A1 (en) 2018-07-25 2020-01-30 Skylinedx B.V. Gene signatures for predicting metastasis of melanoma and patient prognosis
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
CN110257518B (zh) * 2019-07-01 2022-08-02 复旦大学附属中山医院 一种用于预测转移性结直肠癌转化治疗疗效的基因集
US12057959B2 (en) * 2019-12-31 2024-08-06 Mcafee, Llc Device identification
KR102263984B1 (ko) * 2020-02-21 2021-06-11 재단법인 아산사회복지재단 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법
KR102535150B1 (ko) * 2020-04-14 2023-05-23 주식회사 베르티스 암의 예후 예측용 조성물
EP4143309A4 (en) * 2020-04-29 2025-01-01 Freenome Holdings, Inc. Rna markers and methods for identifying colon cell proliferative disorders
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112322730B (zh) * 2020-10-16 2023-04-18 上海市第一人民医院 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN113667673B (zh) * 2021-07-15 2024-02-06 武汉血液中心 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用
KR20230059642A (ko) * 2021-10-26 2023-05-03 사회복지법인 삼성생명공익재단 miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도
CN116735874B (zh) * 2022-03-11 2025-09-23 上海市免疫学研究所 结直肠癌肿瘤边界细胞亚群标志物组合及其应用
WO2024035653A1 (en) * 2022-08-06 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA2330929A1 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
EP1131470A4 (en) 1998-10-28 2004-11-10 Vysis Inc CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS
EP0999016B1 (en) * 1998-11-06 2001-07-11 Temco S. R. L. Cutter for cross cutting of webs
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2390687A1 (en) 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
US7029677B2 (en) * 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001276331A1 (en) 2000-04-06 2001-10-23 Epigenomics Ag Diagnosis of diseases associated with metastasis
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2002012280A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002012328A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030077568A1 (en) 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
AU2002246519A1 (en) 2000-11-20 2002-08-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002074156A2 (en) * 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
JP2005520483A (ja) * 2001-05-09 2005-07-14 ユニバーシティ ホスピタルズ オブ クリーブランド 新規遺伝子マーカーを用いる皮膚に対する紫外線損傷の評価、それに関連する方法及び組成物
US20030148314A1 (en) * 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
WO2003041562A2 (en) 2001-11-14 2003-05-22 Whitehead Institute For Biomedical Research Molecular cancer diagnosis using tumor gene expression signature
US20030148410A1 (en) * 2001-12-10 2003-08-07 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20060046249A1 (en) 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
US7955800B2 (en) 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
EP1552293A4 (en) 2002-09-10 2006-12-06 Guennadi V Glinskii METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES
WO2004110345A2 (en) 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2562835A1 (en) 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
US20060183893A1 (en) 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
JP2008535853A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
KR20090003178A (ko) 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

Also Published As

Publication number Publication date
US8026060B2 (en) 2011-09-27
US8153380B2 (en) 2012-04-10
US20110039272A1 (en) 2011-02-17
EP2400036A1 (en) 2011-12-28
US20130102492A1 (en) 2013-04-25
US20090291434A1 (en) 2009-11-26
US20110039269A1 (en) 2011-02-17
JP5486720B2 (ja) 2014-05-07
US20120171688A1 (en) 2012-07-05
JP2013223503A (ja) 2013-10-31
JP2013215201A (ja) 2013-10-24
EP2412823B1 (en) 2014-09-03
WO2007082099A2 (en) 2007-07-19
JP2013226150A (ja) 2013-11-07
JP5486717B2 (ja) 2014-05-07
DK1974058T3 (da) 2014-09-01
US20110111421A1 (en) 2011-05-12
US8198024B2 (en) 2012-06-12
EP1974058B1 (en) 2014-06-11
EP2412821B1 (en) 2014-09-17
EP2412820A1 (en) 2012-02-01
CA2636984A1 (en) 2007-07-19
US8153379B2 (en) 2012-04-10
US20110097759A1 (en) 2011-04-28
EP2412821A1 (en) 2012-02-01
HK1120089A1 (en) 2009-03-20
NZ569788A (en) 2011-08-26
JP5486718B2 (ja) 2014-05-07
EP2412824B1 (en) 2014-10-08
IL192794A0 (en) 2009-02-11
US8367345B2 (en) 2013-02-05
EP2412823A1 (en) 2012-02-01
JP2013074894A (ja) 2013-04-25
US20100190173A1 (en) 2010-07-29
EP2412822A1 (en) 2012-02-01
EP2407553A1 (en) 2012-01-18
US8153378B2 (en) 2012-04-10
EP2412824A1 (en) 2012-02-01
EP2377950A1 (en) 2011-10-19
US20110039270A1 (en) 2011-02-17
NZ593226A (en) 2012-10-26
JP5486664B2 (ja) 2014-05-07
NO20083461L (no) 2008-10-10
KR20090003178A (ko) 2009-01-09
NZ593224A (en) 2012-10-26
AU2007204826A1 (en) 2007-07-19
US8029995B2 (en) 2011-10-04
JP5486719B2 (ja) 2014-05-07
EP2377950B1 (en) 2014-09-17
EP1974058A2 (en) 2008-10-01
AU2007204826B2 (en) 2013-01-10
JP2009523028A (ja) 2009-06-18
JP2013176398A (ja) 2013-09-09
US20110039271A1 (en) 2011-02-17
NZ593228A (en) 2012-10-26
MX2008008973A (es) 2008-11-26
JP2013226151A (ja) 2013-11-07
US8273537B2 (en) 2012-09-25
US7695913B2 (en) 2010-04-13
BRPI0706511A2 (pt) 2011-03-29
NZ593227A (en) 2012-10-26
NZ593225A (en) 2012-10-26
ES2491222T3 (es) 2014-09-05
NZ593229A (en) 2012-10-26
IL192794A (en) 2013-07-31
WO2007082099A3 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
JP5297202B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP4680898B2 (ja) 癌再発の可能性の予測
ES3027507T3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2008115419A2 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2009114836A1 (en) Gene expression markers for prediction of patient response to chemotherapy
JP2016104014A (ja) 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験
EP3556867A1 (en) Methods to predict clinical outcome of cancer
EP2191020A2 (en) Gene expression markers of recurrence risk in cancer patients after chemotherapy
CN101400804B (zh) 用于结肠直肠癌预后的基因表达标志物
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40014990A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130614

R150 Certificate of patent or registration of utility model

Ref document number: 5297202

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250